Overview

Rosiglitazone in Treating Patients With Liposarcoma

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Maleic acid
Rosiglitazone